Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed with company Medicem to acquire the license rights on Medicem’s IOLs portfolio for territory of Europe and Middle East with option to expand the cooperation to USA and Asia after successful completion of pending clinical studies. Medicem has developed unique bioanalogic intraocular lenses using WIGEL hydrogel material offering additional benefits to patients. The launch of the Medicem portfolio through Valeant is planned in 2016.
"We are excited to expand our presence in the field of surgical ophthalmology and we believe that this deal brings complementary IOL portfolio to our current existing surgical business. Through this product portfolio line we can offer unique solution to patients and support building leading position within IOL field." said Pavel Mirovsky, President of Valeant EMEA.
About Valeant Pharmaceuticals International, Inc.Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
About Medicem International, Medicem International is responsible for the international commercial activities of Medicem Group, an integrated group of biomedical companies focused on researching, developing and commercializing new medical devices. More information about Medicem can be found at www.medicem.com.